Clinical trial
Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)
NCT07913672 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Pilot Study of Live Biotherapeutic Product (LBP) MARCO (Microbiota Augmentation to Reestablish Commensal Organisms) Combined With Ruxolitinibfor Patients With Steroid Refractory or Intolerant Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) After Allogeneic Cell Transplantation (Allo-HCT) (MARCO-GVHD Trial)
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- October 27, 2026
- Completion date
- October 27, 2028
- Enrollment
- 16 (estimated)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
transplant failure or rejection of bone marrow (graft vs host disease, gvhd)
Arms
As registered; 3 arms.
-
Consortia A
Participants in Cohort 1 will receive LBP-MARCO with the same combination of 7 specific types of bacteria.
-
Consortia B
If the bacteria do not grow or produce enough metabolites, the next group of participants (Cohort 2) will get LBP-MARCO with a different combination of bacteria.
-
Consortia C
If that combination does not grow in participants' guts, the next group of participants (Cohort 3) will get LBP-MARCO with a different combination of the bacteria.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
incidence and severity of SAEs
Grade 2-4 infections by CTCAE v6 either clinically or microbiologically will be assessed throughout the study until day +100. Causality and relationship with aGVHD, LBP-MARCO, and ruxolitinib will be determined.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Ruxolitinib
- US 11602536; expires May 5, 2041; assignee Incyte Corp
- US 11510923; expires September 4, 2040; assignee Incyte Corp
- US 11590137; expires September 4, 2040; assignee Incyte Corp
- US 12589096; expires September 4, 2040; assignee not stated
- US 12233067; expires July 28, 2040; assignee Incyte Corp
- +29 more patents
Lead sponsor's other trials
Memorial Sloan Kettering Cancer Center, most recent start first.
+1,958 more trials See the organization page
Similar trials
Same condition (Graft vs Host Disease) and phase, most recent start first.
+90 more trials See the condition page